Arnout F Gerritsen

USPTO Granted Patents = 19 (Patent Applications = 3)

CIPO Patents = 2

EPO Patents = 8 (Patent Applications = 1)

Average Co-Inventor Count = 6.9

ph-index = 7

Forward Citations = 356(Granted Patents)

Location History:

Bunnik, NL (2006 - 2016)
Utrecht, NL (2019 - 2023)

Company Filing History:

Years Active: 2006-2025

Loading Chart...

19 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12331123 - Agent, uses and methods for treatment (2025-06-17),

2. 12247065 - Method for producing a controlled mixture of two or more different antibodies (2025-03-11),

3. 11548950 - Agent, uses and methods for treatment (2023-01-10),

4. 11492371 - Production of heterodimeric proteins (2022-11-08),

5. 10894833 - Agents, uses and methods for treatment (2021-01-19),

6. 10889650 - Agent, uses and methods for treatment (2021-01-12),

7. 10479835 - Agent, uses and methods for treatment (2019-11-19),

8. 10428147 - Anti-sortilin antibodies, uses and methods for treatment (2019-10-01),

9. 10344050 - Production of heterodimeric proteins (2019-07-09),

10. 9458236 - Human monoclonal antibodies to epidermal growth factor receptor (EGFR) (2016-10-04),

11. 8586041 - Human monoclonal antibodies to epidermal growth factor receptor (EGFR) (2013-11-19),

12. 7850962 - Human monoclonal antibodies against CD20 (2010-12-14),

13. 7597892 - Method for treating psoriasis by administering human antibodies specific for Interleukin 15 (IL-15) (2009-10-06),

14. 7595378 - Human monoclonal antibodies to epidermal growth factor receptor (EGFR) (2009-09-29),

15. 7585961 - Nucleic acid encoding human antibodies specific for interleukin 15 (IL-15) (2009-09-08),

Title: Insights into the Innovative Contributions of Arnout F Gerritsen

Introduction: Arnout F Gerritsen, based in Bunnik, Netherlands, is a prolific inventor with a total of 19 patents to his name. His innovative work primarily revolves around advancements in the field of biotechnology, particularly the development and production of antibodies for therapeutic applications.

Latest Patents: Among his notable recent inventions, one patent focuses on monoclonal anti-Sortilin antibodies. These antibodies have been identified as instrumental in correcting deficient levels of progranulin (PGRN), which can play a significant role in treating conditions such as frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). Another significant patent outlines a method for producing a controlled mixture of two or more different antibodies. This method utilizes chromatography, ensuring a consistent composition that is crucial for drug product applications, allowing for a predetermined ratio of antibodies to be produced efficiently.

Career Highlights: Arnout has made substantial contributions to the biotechnology sector through his associations with leading companies. He has worked with Genmab A/S, a company renowned for its innovative therapies in antibody-based treatments. Additionally, he has been part of H. Lundbeck A/S, a global pharmaceutical company dedicated to improving the lives of people with brain disorders.

Collaborations: Throughout his career, Arnout F Gerritsen has worked closely with esteemed colleagues, including Jan G J Van De Winkel and Marcus A Van Dijk. These collaborations have further enriched the innovation landscape in which he operates, combining expertise and knowledge to push the boundaries of medical research.

Conclusion: Arnout F Gerritsen stands out as a key inventor in the biotechnology field, with a commendable portfolio of patents aimed at addressing critical health challenges. His work continues to pave the way for new therapeutic avenues and showcases the impact of innovation in medicine.

This text is generated by artificial intelligence and may not be accurate.